FREE Educational Dinner -- Gamifant for MAS in Still's Disease

The AACN Chapter at UCLA collaborates with Sobi and other healthcare professionals to bring you a presentation featuring an overview of Macrophage Activation Syndrome (MAS) in known or suspected Still's disease and treatment with Gamifant.

Gamifant® (emapalumab-lzsg) is an interferon gamma (IFNγ)–blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

The session will include an in-depth look at Gamifant as an interferon gamma–blocking antibody treatment option and a Q&A segment for additional information.